Remove legal-notices
article thumbnail

STAT+: FDA gives a mixed response to a petition seeking greater clinical trial transparency

STAT

In response to a citizen’s petition filed a year ago, the agency indicated it is unlikely to levy fines or take a more stringent approach to issue so-called non-compliance notices because the process could strain its resources.

FDA 139
article thumbnail

STAT+: FTC warns drugmakers they can face legal action over improper patent listings

STAT

The Federal Trade Commission warned pharmaceutical companies they could face legal action if they improperly list patents for brand-name medicines in a Food and Drug Administration registry, the latest effort by the federal government to scrutinize patent moves by drugmakers.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Conference Notebook: ACI’s Cosmetics and Personal Care Products Conference

The FDA Law Blog

Now in the second year of implementation, companies have started noticing the consequences as FDA implements the new requirements and develops regulations and guidance. An interesting notice from the conference discussion on PFAS is that, to date, very few if any PFAS class action suits have alleged actual, realized harm from the chemicals.

FDA 64
article thumbnail

STAT+: Pharmalittle: Pfizer will not license generic Covid-19 pill in China; BioMarin signs outcomes-based deal in Germany for gene therapy

STAT

The company expects its Covid-19 antiviral pill to be launched in the Chinese market on Friday, but noted that Sinopharm is the only legally authorized distributor there of molnupiravir, which is sold under the brand name Lagevrio and was developed by Merck and Ridgeback Biotherapeutics. Have a wonderful day, and please do stay in touch.

article thumbnail

The Streams Have Been Crossed: FTC Enters FDA Territory

The FDA Law Blog

Mass hysteria! ” At least that’s this blogger’s reaction to the recent news that FTC sent out Notice letters to 10 different drug companies about the patent information they list in the Orange Book. Indeed, that one line in the Notice letters FTC sent may end up being really critical if companies don’t willingly de-list.

FDA 59
article thumbnail

Updates to the PMHNP Board Exam for 2023

Board Vitals - Pharmacist

It is less likely to be noticed by a less-experienced practitioner. It is less likely to be noticed by a non-specialist (e.g. Question 1 Adjustment disorders are frequently referred to as “subthreshold” diagnoses. How does this “subthreshold” diagnosis relate to the patient’s overall health?

96
article thumbnail

FDA’s Summer Plans May Include LDT Rulemaking

The FDA Law Blog

The Notice of Proposed Rulemaking (NPRM) for LDTs is scheduled to be published in the Federal Register in August. And regulating LDTs through guidance documents is vulnerable to legal challenge on procedural grounds. Whether we will actually see a proposed rule in August is more than a little uncertain, however.

FDA 56